The potential therapeutic effect of platelet-rich plasma in the treatment of post-COVID-19 parosmia
Egyptian Journal of Otolaryngology
; 38(1) (no pagination), 2022.
Article
in English
| EMBASE | ID: covidwho-2312143
ABSTRACT
Background:
COVID-19-related olfactory dysfunction is an emerging problem with a significant impact on the quality of life of affected individuals. Different lines of treatment have been used with varying results. This study aimed to assess the potential therapeutic effect of PRP in the treatment of post-COVID olfactory dysfunction. This work aimed to assess the potential therapeutic effect of platelet-rich plasma (PRP) in treating post-COVID-19 parosmia. A pilot study was conducted on 60 patients with post-COVID parosmia without responding to a 3-month course of olfactory training, topical corticosteroids, omega-three, vitamin B12, and zinc supplementation. The patients were distributed randomly and equally among 2 groups. The case group was subjected to three PRP injections in the olfactory cleft at 3 weeks intervals. The control group continued the pre-study treatment protocol for 6 weeks. The degree of parosmia was assessed before and after treatment subjectively using a visual analog scale (VAS) from 0 to 10. Reaching 0-1 on the visual analog scale was a complete improvement. The primary outcome was assessing the post-treatment score for parosmia 1 month after the third injection in the case group. The second outcome was the comparison between both groups regarding the degree of improvement 1 month after cessation of treatment. Result(s) There was a highly significant improvement in VAS for parosmia (p < 0.00001) in the case group and a significant improvement in VAS for parosmia in the control group (p = P = 0.00148). There was a significant difference between both groups regarding the degree of improvement favoring the case group (p = 0.002). Conclusion(s) Platelet-rich plasma injection in the olfactory cleft offers a therapeutic option for treating patients with post-COVID-19 olfactory parosmia who failed to respond to traditional conservative treatment.Copyright © 2022, The Author(s).
covid-19; Olfactory dysfunction; Parosmia; Platelet-rich plasma; adult; article; clinical outcome; clinical protocol; controlled study; coronavirus disease 2019; corticosteroid therapy; female; human; major clinical study; male; mineral supplementation; olfactory training; parosmia/co [Complication]; parosmia/dt [Drug Therapy]; parosmia/rh [Rehabilitation]; parosmia/th [Therapy]; pilot study; randomized controlled trial; smelling disorder/th [Therapy]; therapy effect; thrombocyte rich plasma; treatment duration; treatment response; treatment withdrawal; visual analog scale; vitamin supplementation; corticosteroid/ct [Clinical Trial]; corticosteroid/dt [Drug Therapy]; corticosteroid/tp [Topical Drug Administration]; cyanocobalamin/ct [Clinical Trial]; cyanocobalamin/dt [Drug Therapy]; omega 3 fatty acid/ct [Clinical Trial]; omega 3 fatty acid/dt [Drug Therapy]; zinc/ct [Clinical Trial]; zinc/dt [Drug Therapy]
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Experimental Studies
Topics:
Long Covid
Language:
English
Journal:
Egyptian Journal of Otolaryngology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS